Dapagliflozin, an SGLT2 inhibitor, has been shown to reduce renal injury even in the absence of diabetes, through inhibition of the NLRP3 inflammasome, protecting against kidney fibrosis (Ke et al., 2022). This evidence concerns the gene NLRP3 and diabetes mellitus.